---
title: "Roth MKM Sticks to Their Buy Rating for Insmed (INSM)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/276094748.md"
description: "Roth MKM analyst Adam Walsh has maintained a Buy rating on Insmed (INSM) with a price target of $212.00. Walsh, a 3-star analyst with a 43.81% success rate, focuses on the Healthcare sector. Insmed also received a Buy rating from Goldman Sachs’s Andrea Newkirk on February 11, while TipRanks reiterated a Hold rating on February 3."
datetime: "2026-02-17T05:05:38.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/276094748.md)
  - [en](https://longbridge.com/en/news/276094748.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/276094748.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/276094748.md) | [繁體中文](https://longbridge.com/zh-HK/news/276094748.md)


# Roth MKM Sticks to Their Buy Rating for Insmed (INSM)

Roth MKM analyst Adam Walsh maintained a Buy rating on Insmed yesterday and set a price target of $212.00.

### President's Day Sale - 70% Off

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

According to TipRanks, Walsh is a 3-star analyst with an average return of 6.0% and a 43.81% success rate. Walsh covers the Healthcare sector, focusing on stocks such as Insmed, Arcturus Therapeutics, and vTv Therapeutics.

In addition to Roth MKM, Insmed also received a Buy from Goldman Sachs’s Andrea Newkirk in a report issued on February 11. However, on February 3, TipRanks – OpenAI reiterated a Hold rating on Insmed (NASDAQ: INSM).

### Related Stocks

- [Insmed Incorporated (INSM.US)](https://longbridge.com/en/quote/INSM.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md)
- [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [BNY Mellon Innovators ETF (BKIV.US)](https://longbridge.com/en/quote/BKIV.US.md)
- [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md)
- [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md)
- [Invesco Dorsey Wright Healthcare MomtETF (PTH.US)](https://longbridge.com/en/quote/PTH.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)

## Related News & Research

- [Structure Therapeutics Reports Strong Phase 2 Obesity Drug Results](https://longbridge.com/en/news/279269040.md)
- [Will KETAFREE Become The First FDA-Approved Preservative-Free Ketamine Formulation?](https://longbridge.com/en/news/279285510.md)
- [Vanderbilt Report: Artelo Biosciences Expands Into $16.3 Billion Glaucoma Market With Fully Funded Clinical Study | ARTL Stock News](https://longbridge.com/en/news/279594805.md)
- [Mirum Pharmaceuticals Executives Sell Shares](https://longbridge.com/en/news/279503772.md)
- [NRx Pharma Says FDA Identifies No Bioequivalence Issues In Preservative-free Ketamine Application](https://longbridge.com/en/news/279426124.md)